By disrupting critical pathways involved in TAM polarization and EMT, simvastatin can restore sensitivity to chemotherapy and offer a new strategy to combat resistance in EGFR-TKI-treated NSCLC (Jin et al., 2019). Here, EGFR is linked to non-small cell lung carcinoma.